Two large Icelandic and US studies [41], [42], including in combination >28 000 participants, tested an overlapping set of eight prostate cancer or PSA-risk SNPs prioritized from GWAS for an association with LUTS or LUTS medication use. Here, KLK3 is linked to prostate carcinoma.